Suppr超能文献

孕期止吐药处方配药情况:挪威762437例妊娠的药物利用研究

Antiemetic Prescription Fills in Pregnancy: A Drug Utilization Study Among 762,437 Pregnancies in Norway.

作者信息

van Gelder Marleen M H J, Nordeng Hedvig

机构信息

Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.

Radboud REshape Innovation Center, Radboud University Medical Center, Nijmegen, the Netherlands.

出版信息

Clin Epidemiol. 2021 Feb 26;13:161-174. doi: 10.2147/CLEP.S287892. eCollection 2021.

Abstract

OBJECTIVE

To determine antiemetic prescription fill patterns during pregnancy in Norway, with special focus on the use of ondansetron and recurrent use in subsequent pregnancies.

METHODS

We conducted a population-based registry study based on data from the Medical Birth Registry of Norway linked to the Norwegian Prescription Database for 762,437 pregnancies >12 gestational weeks ending in live or non-live births between 2005 and 2017. Prescription fills of medications used for nausea and vomiting of pregnancy were summarized in treatment pathways to determine drug utilization patterns. Logistic regression analyses were used to estimate associations between maternal and pregnancy characteristics and antiemetic prescription fills.

RESULTS

The prescription fill rate for antiemetic medication during pregnancy was 7.6%. However, prescription fill rates were 35.5% in the second pregnancy after filling an antiemetic prescription in the first pregnancy and 53.5% for women who filled antiemetic prescriptions in the previous 2 pregnancies. Among pregnancies with antiemetic prescription fills, 62.2% were dispensed metoclopramide, 28.2% meclizine, and 17.2% promethazine. First-line treatment started with monotherapy in 97.4% of these pregnancies, which was the only treatment received in 78.7%. Prescriptions for ondansetron were filled in 0.3% of pregnancies, with 76.9% being initially filled in the first trimester. Ondansetron as first-line prescription medication and/or use in the first trimester was associated with proxies for more severe nausea and vomiting of pregnancy, including a diagnosis of hyperemesis gravidarum, multiple gestations, a higher obstetric comorbidity index, and concomitant use of medication for gastroesophageal reflux disease and nervous system medications. Women who filled an antiemetic prescription in their first pregnancy were less likely to have subsequent pregnancies than women who did not fill an antiemetic prescription in their first pregnancy (OR 0.93, 95% CI 0.90-0.96).

CONCLUSION

Complex patterns of antiemetic prescription fills in pregnancy may mirror the challenge of optimal management of nausea and vomiting of pregnancy in clinical practice, especially for women with severe symptoms.

摘要

目的

确定挪威孕期止吐药物的处方配药模式,特别关注昂丹司琼的使用情况以及后续妊娠中的重复使用情况。

方法

我们基于挪威医疗出生登记处的数据进行了一项基于人群的登记研究,该数据与挪威处方数据库相链接,涵盖了2005年至2017年间762,437例妊娠周数大于12周且以活产或死产告终的妊娠情况。用于妊娠恶心和呕吐的药物处方配药情况在治疗路径中进行了总结,以确定药物使用模式。采用逻辑回归分析来估计孕产妇和妊娠特征与止吐药物处方配药之间的关联。

结果

孕期止吐药物的处方配药率为7.6%。然而,在首次妊娠开具止吐处方后的第二次妊娠中,处方配药率为35.5%,在前两次妊娠中均开具止吐处方的女性中,这一比例为53.5%。在有止吐药物处方配药的妊娠中,62.2%配用了甲氧氯普胺,28.2%配用了美克洛嗪,17.2%配用了异丙嗪。在这些妊娠中,97.4%的一线治疗起始于单一疗法,其中78.7%的妊娠仅接受了这一治疗。0.3%的妊娠开具了昂丹司琼处方,其中76.9%最初是在孕早期开具的。昂丹司琼作为一线处方药和/或在孕早期使用与妊娠恶心和呕吐更严重的指标相关,包括妊娠剧吐的诊断、多胎妊娠、更高的产科合并症指数以及同时使用治疗胃食管反流病的药物和神经系统药物。在首次妊娠开具止吐处方的女性比未在首次妊娠开具止吐处方的女性后续妊娠的可能性更低(比值比0.93,95%置信区间0.90 - 0.96)。

结论

孕期止吐药物的复杂处方配药模式可能反映了临床实践中妊娠恶心和呕吐最佳管理的挑战,尤其是对于症状严重的女性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2776/7924249/8fe1d09505bb/CLEP-13-161-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验